Synergistic Therapy for Invasive Fungal Infection

Opportunistic invasive fungal infections are an emerging problem worldwide and are often severe and fatal in hospital inpatients or patients under immunosuppression. Because of its high mortality, early initiation of appropriate antifungal treatment is important to improve the outcomes of patients. Unfortunately, the applicable antifungal options are very limited. The approved antifungal agents for treating invasive fungal infection only contain a few classes, such as azoles, polyenes, echinocandins, and flucytosine. Additionally, antifungal resistance has been increasingly reported, especially the pan-resistance of azoles, which further minimized the arsenal of antifungal drugs. Under such a dilemma, the combination therapy with novel compounds and antifungal agents, which has the potential to improve treatment efficacy, reduce side effects, and decrease the probability of developing resistance, represents a valuable and promising alternative option to antifungal monotherapy.

This Research Topic is focused on the investigation of novel antifungal treatment regimes, including in vitro and/or in vivo studies that may facilitate future antifungal therapy, especially for invasive fungal infection. We welcome the submission of Original Research and Review articles, following on the below aspects:

1. Novel chemicals, Peptides, Herb extracts, Derivants with the antifungal ability or synergistic effects with approved antifungal agents.
2. Novel in vivo model for fungal infection
3. Drugs reverse the resistance of fungi or their biofilm
4. Mechanisms of action and synergy with drugs against fungal pathogens